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Recent advances in immunotherapy have led to eﬀective
treatments for patients with diﬀerent diseases including
cancer. The use of immune checkpoint-blocking monoclonal
antibodies (CPB) and adoptive cellular therapy induces long-
term clinical beneﬁts in a number of advanced cancer
patients. However, CPB treatment beneﬁts only a small frac-
tion of patients and can be outweighed by autoimmune tox-
icity, while the adoptive cell therapy approach is complex and
requires the culture and transduction of patient-speciﬁc
immune cells, which can be time-consuming and costly.
Cancer vaccines are considered to be a promising alternative,
but most trials have failed miserably, apart from the ones tar-
geting virus-associated cancers. A better understanding of
the immunological mechanisms is thus crucial in advancing
the development of immunotherapy.
In this special issue, seven original research studies and
three review articles highlight some recent discoveries in
immunotherapy and vaccine development. On vaccine
design and development, S. Heinimäki et al. investigated
the importance of delivering the VLP-based norovirus vac-
cine mucosally to induce not only systemic but also the
desired mucosal antibody responses. Also, B. Behrouz et al.
followed a mucosal vaccination approach and used bivalent
ﬂagellin as an immunogen, which induced humoral and cel-
lular immune responses and protected mice from Pseudomo-
nas aeruginosa-mediated acute pneumonia. S. Choi et al.
assessed if the Mycobacterium tuberculosis (Mtb) protein
Rv3841, which plays a crucial role in the growth of Mtb,
can also serve as a vaccine target. They found that the protein
activated dendritic cells (DCs) induced Th1 responses, which
could inhibit mycobacterial growth. The topic of antigen
production in plants is covered in the article by P.-F. Liu
et al. They expressed staphylococcal enterotoxin B in radish
leaves by agroinﬁltration and showed antibody induction
against the antigen after immunizing mice with homoge-
nized leaves. In the area of immunotherapy for autoimmune
diseases, J. Yang et al. showed that tolerogenic DCs could
expand TGFβ-induced regulatory T cells (iTregmtDC),
which reduced the severity of collagen-induced arthritis in
mice. This implies that iTregmtDC might have a therapeutic
potential in autoimmune arthritis. For adjuvant studies,
J. Laiño et al. described that the dual TLR2/7 ligands,
CL413, and CL53, could suppress allergic Th2 immune
responses in mice and could act as potential adjuvants for
allergy treatment. In the ﬁeld of animal models for studying
immunotherapies and vaccine strategy, C. Leung analyzed
the oncofetal antigen ROR1 expression in humanized mice
and suggested that humanized mice could be a useful tool
to study B cell malignant diseases. In the ﬁrst of the
review articles, A. P. F. Costa et al. carried out a meta-
analysis of studies on the safety of the recently introduced
nonavalent prophylactic HPV vaccine, which they showed
to be as safe as the quadrivalent one. On immunotherapy,
S. Sun et al. reviewed the strategies to overcome the toxic-
ities of chimeric antigen receptor (CAR) T cell therapy. In
addition, F.-S. Hsu et al. gave a comprehensive review on
the use of immune checkpoint inhibitors for treating
urothelial carcinoma.
In conclusion, these articles have showcased some novel
advances inmultiple topicswithin theﬁeld of immunotherapy
and vaccine development. We hope the readers will be stimu-
lated by and ﬁnd applications of the interesting ﬁndings.
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